MediWound (NASDAQ:MDWD) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $17.73 and traded as high as $18.67. MediWound shares last traded at $18.55, with a volume of 46,268 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MDWD shares. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Zacks Research lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $32.25.

MediWound Stock Up 2.7%

The company has a market cap of $205.72 million, a PE ratio of -7.03 and a beta of 0.27. The stock’s 50 day moving average is $17.73 and its 200-day moving average is $18.77.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). The business had revenue of $5.71 million for the quarter, compared to analysts’ expectations of $5.68 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. On average, analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. Corebridge Financial Inc. raised its stake in MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares in the last quarter. Deutsche Bank AG raised its stake in MediWound by 2,255.2% during the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 6,044 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in MediWound during the first quarter valued at $168,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.